Novo Disappoints Investors After Losing Obesity Market Lead To Eli Lilly
Guidance·1 article across 1 outlet
Story updated Rewritten when the story materially grows; the wire is checked every 15 minutesAbout this data
Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.
Investors were looking for more robust sales targets, but the company's presentation did not meet those expectations.
Novo NordiskEli LillyMike Doustdar
Sources
Every quote below is verbatim from the article it is attributed to.
SourceReports the news
“Novo Nordisk A/S disappointed investors hoping for more concrete turnaround plans from Chief Executive Officer Mike Doustdar after the Danish drugmaker lost its lead in the booming obesity market to Eli Lilly & Co.”
Bloomberg — Novo Disappoints Investors Who Sought More Robust Sales Targets